---
document_datetime: 2025-11-23 08:05:02
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/medicines/human/EPAR/rivastigmine-teva.html
document_name: rivastigmine-teva.html
version: success
processing_time: 0.1054972
conversion_datetime: 2025-12-28 12:36:04.950179
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
# Rivastigmine Teva

[RSS](/en/individual-human-medicine.xml/65628)

##### Withdrawn

This medicine's authorisation has been withdrawn

rivastigmine

Medicine

Human

Withdrawn

Page contents

## Page contents

- [Overview](#overview)
- [Product information](#product-info)
- [Product details](#product-details)
- [Authorisation details](#authorisation-details)
- [Assessment history](#assessment-history)

- Application under evaluation
- CHMP opinion
- European Commission decision

## Overview

On the 17 April 2009 the European Commission issued a marketing authorisation valid throughout the European Union for the medicinal product Rivastigmine Teva (Rivastigmine) which was approved for the symptomatic treatment of patients with mild to moderately severe Alzheimer's dementia and symptomatic treatment of mild to moderately severe dementia in patients with idiopathic Parkinson's disease. The marketing authorisation holder (MAH) responsible for Rivastigmine Teva was Teva Pharma B.V.

The European Commission was notified by a letter dated 24 August 2012 of the MAH's decision to voluntarily withdraw the marketing authorisation as of the Commission Decision date for Rivastigmine Teva for commercial reasons. Rivastigmine Teva was only marketed in Romania. On 10 September 2012 the European Commission issued a decision to withdraw the marketing authorisation for Rivastigmine Teva.

Pursuant to this decision the European Public Assessment Report for Rivastigmine Teva is updated to reflect that the marketing authorisation is no longer valid.

Rivastigmine Teva : EPAR - Summary for the public

English (EN) (261.34 KB - PDF)

**First published:** 08/05/2009

**Last updated:** 27/09/2012

[View](/en/documents/overview/rivastigmine-teva-epar-summary-public_en.pdf)

[Other languages (21)](#file-language-dropdown-438)

български (BG) (423.44 KB - PDF)

**First published:**

08/05/2009

**Last updated:**

27/09/2012

[View](/bg/documents/overview/rivastigmine-teva-epar-summary-public_bg.pdf)

español (ES) (262.58 KB - PDF)

**First published:**

08/05/2009

**Last updated:**

27/09/2012

[View](/es/documents/overview/rivastigmine-teva-epar-summary-public_es.pdf)

čeština (CS) (395.3 KB - PDF)

**First published:**

08/05/2009

**Last updated:**

27/09/2012

[View](/cs/documents/overview/rivastigmine-teva-epar-summary-public_cs.pdf)

dansk (DA) (262.01 KB - PDF)

**First published:**

08/05/2009

**Last updated:**

27/09/2012

[View](/da/documents/overview/rivastigmine-teva-epar-summary-public_da.pdf)

Deutsch (DE) (499.95 KB - PDF)

**First published:**

08/05/2009

**Last updated:**

27/09/2012

[View](/de/documents/overview/rivastigmine-teva-epar-summary-public_de.pdf)

eesti keel (ET) (261.35 KB - PDF)

**First published:**

08/05/2009

**Last updated:**

27/09/2012

[View](/et/documents/overview/rivastigmine-teva-epar-summary-public_et.pdf)

ελληνικά (EL) (420.4 KB - PDF)

**First published:**

08/05/2009

**Last updated:**

27/09/2012

[View](/el/documents/overview/rivastigmine-teva-epar-summary-public_el.pdf)

français (FR) (262.84 KB - PDF)

**First published:**

08/05/2009

**Last updated:**

27/09/2012

[View](/fr/documents/overview/rivastigmine-teva-epar-summary-public_fr.pdf)

italiano (IT) (262.38 KB - PDF)

**First published:**

08/05/2009

**Last updated:**

27/09/2012

[View](/it/documents/overview/rivastigmine-teva-epar-summary-public_it.pdf)

latviešu valoda (LV) (400.85 KB - PDF)

**First published:**

08/05/2009

**Last updated:**

27/09/2012

[View](/lv/documents/overview/rivastigmine-teva-epar-summary-public_lv.pdf)

lietuvių kalba (LT) (373.57 KB - PDF)

**First published:**

08/05/2009

**Last updated:**

27/09/2012

[View](/lt/documents/overview/rivastigmine-teva-epar-summary-public_lt.pdf)

magyar (HU) (386.87 KB - PDF)

**First published:**

08/05/2009

**Last updated:**

27/09/2012

[View](/hu/documents/overview/rivastigmine-teva-epar-summary-public_hu.pdf)

Malti (MT) (400.17 KB - PDF)

**First published:**

08/05/2009

**Last updated:**

27/09/2012

[View](/mt/documents/overview/rivastigmine-teva-epar-summary-public_mt.pdf)

Nederlands (NL) (262.67 KB - PDF)

**First published:**

08/05/2009

**Last updated:**

27/09/2012

[View](/nl/documents/overview/rivastigmine-teva-epar-summary-public_nl.pdf)

polski (PL) (403.91 KB - PDF)

**First published:**

08/05/2009

**Last updated:**

27/09/2012

[View](/pl/documents/overview/rivastigmine-teva-epar-summary-public_pl.pdf)

português (PT) (262.56 KB - PDF)

**First published:**

08/05/2009

**Last updated:**

27/09/2012

[View](/pt/documents/overview/rivastigmine-teva-epar-summary-public_pt.pdf)

română (RO) (369.47 KB - PDF)

**First published:**

08/05/2009

**Last updated:**

27/09/2012

[View](/ro/documents/overview/rivastigmine-teva-epar-summary-public_ro.pdf)

slovenčina (SK) (391.71 KB - PDF)

**First published:**

08/05/2009

**Last updated:**

27/09/2012

[View](/sk/documents/overview/rivastigmine-teva-epar-summary-public_sk.pdf)

slovenščina (SL) (383.63 KB - PDF)

**First published:**

08/05/2009

**Last updated:**

27/09/2012

[View](/sl/documents/overview/rivastigmine-teva-epar-summary-public_sl.pdf)

Suomi (FI) (261.66 KB - PDF)

**First published:**

08/05/2009

**Last updated:**

27/09/2012

[View](/fi/documents/overview/rivastigmine-teva-epar-summary-public_fi.pdf)

svenska (SV) (261.87 KB - PDF)

**First published:**

08/05/2009

**Last updated:**

27/09/2012

[View](/sv/documents/overview/rivastigmine-teva-epar-summary-public_sv.pdf)

## Product information

Rivastigmine Teva : EPAR - Product Information

English (EN) (2.28 MB - PDF)

**First published:** 06/07/2009

**Last updated:** 27/09/2012

[View](/en/documents/product-information/rivastigmine-teva-epar-product-information_en.pdf)

[Other languages (23)](#file-language-dropdown-496)

български (BG) (4.15 MB - PDF)

**First published:**

06/07/2009

**Last updated:**

27/09/2012

[View](/bg/documents/product-information/rivastigmine-teva-epar-product-information_bg.pdf)

español (ES) (1.71 MB - PDF)

**First published:**

06/07/2009

**Last updated:**

27/09/2012

[View](/es/documents/product-information/rivastigmine-teva-epar-product-information_es.pdf)

čeština (CS) (1.93 MB - PDF)

**First published:**

06/07/2009

**Last updated:**

27/09/2012

[View](/cs/documents/product-information/rivastigmine-teva-epar-product-information_cs.pdf)

dansk (DA) (1018.67 KB - PDF)

**First published:**

06/07/2009

**Last updated:**

27/09/2012

[View](/da/documents/product-information/rivastigmine-teva-epar-product-information_da.pdf)

Deutsch (DE) (1.76 MB - PDF)

**First published:**

06/07/2009

**Last updated:**

27/09/2012

[View](/de/documents/product-information/rivastigmine-teva-epar-product-information_de.pdf)

eesti keel (ET) (821.55 KB - PDF)

**First published:**

06/07/2009

**Last updated:**

27/09/2012

[View](/et/documents/product-information/rivastigmine-teva-epar-product-information_et.pdf)

ελληνικά (EL) (2.64 MB - PDF)

**First published:**

06/07/2009

**Last updated:**

27/09/2012

[View](/el/documents/product-information/rivastigmine-teva-epar-product-information_el.pdf)

français (FR) (860.43 KB - PDF)

**First published:**

06/07/2009

**Last updated:**

27/09/2012

[View](/fr/documents/product-information/rivastigmine-teva-epar-product-information_fr.pdf)

íslenska (IS) (954.26 KB - PDF)

**First published:**

06/07/2009

**Last updated:**

27/09/2012

[View](/is/documents/product-information/rivastigmine-teva-epar-product-information_is.pdf)

italiano (IT) (892.86 KB - PDF)

**First published:**

06/07/2009

**Last updated:**

27/09/2012

[View](/it/documents/product-information/rivastigmine-teva-epar-product-information_it.pdf)

latviešu valoda (LV) (3.07 MB - PDF)

**First published:**

06/07/2009

**Last updated:**

27/09/2012

[View](/lv/documents/product-information/rivastigmine-teva-epar-product-information_lv.pdf)

lietuvių kalba (LT) (1.05 MB - PDF)

**First published:**

06/07/2009

**Last updated:**

27/09/2012

[View](/lt/documents/product-information/rivastigmine-teva-epar-product-information_lt.pdf)

magyar (HU) (1.72 MB - PDF)

**First published:**

06/07/2009

**Last updated:**

27/09/2012

[View](/hu/documents/product-information/rivastigmine-teva-epar-product-information_hu.pdf)

Malti (MT) (1.79 MB - PDF)

**First published:**

06/07/2009

**Last updated:**

27/09/2012

[View](/mt/documents/product-information/rivastigmine-teva-epar-product-information_mt.pdf)

Nederlands (NL) (881.7 KB - PDF)

**First published:**

06/07/2009

**Last updated:**

27/09/2012

[View](/nl/documents/product-information/rivastigmine-teva-epar-product-information_nl.pdf)

norsk (NO) (873.22 KB - PDF)

**First published:**

06/07/2009

**Last updated:**

27/09/2012

[View](/no/documents/product-information/rivastigmine-teva-epar-product-information_no.pdf)

polski (PL) (3.36 MB - PDF)

**First published:**

06/07/2009

**Last updated:**

27/09/2012

[View](/pl/documents/product-information/rivastigmine-teva-epar-product-information_pl.pdf)

português (PT) (2.27 MB - PDF)

**First published:**

06/07/2009

**Last updated:**

27/09/2012

[View](/pt/documents/product-information/rivastigmine-teva-epar-product-information_pt.pdf)

română (RO) (1.05 MB - PDF)

**First published:**

06/07/2009

**Last updated:**

27/09/2012

[View](/ro/documents/product-information/rivastigmine-teva-epar-product-information_ro.pdf)

slovenčina (SK) (1.79 MB - PDF)

**First published:**

06/07/2009

**Last updated:**

27/09/2012

[View](/sk/documents/product-information/rivastigmine-teva-epar-product-information_sk.pdf)

slovenščina (SL) (1.82 MB - PDF)

**First published:**

06/07/2009

**Last updated:**

27/09/2012

[View](/sl/documents/product-information/rivastigmine-teva-epar-product-information_sl.pdf)

Suomi (FI) (846.15 KB - PDF)

**First published:**

06/07/2009

**Last updated:**

27/09/2012

[View](/fi/documents/product-information/rivastigmine-teva-epar-product-information_fi.pdf)

svenska (SV) (1.02 MB - PDF)

**First published:**

06/07/2009

**Last updated:**

27/09/2012

[View](/sv/documents/product-information/rivastigmine-teva-epar-product-information_sv.pdf)

**Latest procedure affecting product information:** IB/0008/G 10/09/2012

icon globe

<!-- image -->

This medicine's product information is available in all **official EU languages** . Select 'available languages' to access the language you need.

Product information documents contain:

- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).

Rivastigmine Teva : EPAR - All Authorised presentations

English (EN) (228.43 KB - PDF)

**First published:** 08/05/2009

**Last updated:** 27/09/2012

[View](/en/documents/all-authorised-presentations/rivastigmine-teva-epar-all-authorised-presentations_en.pdf)

[Other languages (23)](#file-language-dropdown-720)

български (BG) (315.28 KB - PDF)

**First published:**

08/05/2009

**Last updated:**

27/09/2012

[View](/bg/documents/all-authorised-presentations/rivastigmine-teva-epar-all-authorised-presentations_bg.pdf)

español (ES) (228.79 KB - PDF)

**First published:**

08/05/2009

**Last updated:**

27/09/2012

[View](/es/documents/all-authorised-presentations/rivastigmine-teva-epar-all-authorised-presentations_es.pdf)

čeština (CS) (304.54 KB - PDF)

**First published:**

08/05/2009

**Last updated:**

27/09/2012

[View](/cs/documents/all-authorised-presentations/rivastigmine-teva-epar-all-authorised-presentations_cs.pdf)

dansk (DA) (229.13 KB - PDF)

**First published:**

08/05/2009

**Last updated:**

27/09/2012

[View](/da/documents/all-authorised-presentations/rivastigmine-teva-epar-all-authorised-presentations_da.pdf)

Deutsch (DE) (228.83 KB - PDF)

**First published:**

08/05/2009

**Last updated:**

27/09/2012

[View](/de/documents/all-authorised-presentations/rivastigmine-teva-epar-all-authorised-presentations_de.pdf)

eesti keel (ET) (228.75 KB - PDF)

**First published:**

08/05/2009

**Last updated:**

27/09/2012

[View](/et/documents/all-authorised-presentations/rivastigmine-teva-epar-all-authorised-presentations_et.pdf)

ελληνικά (EL) (313.73 KB - PDF)

**First published:**

08/05/2009

**Last updated:**

27/09/2012

[View](/el/documents/all-authorised-presentations/rivastigmine-teva-epar-all-authorised-presentations_el.pdf)

français (FR) (229 KB - PDF)

**First published:**

08/05/2009

**Last updated:**

27/09/2012

[View](/fr/documents/all-authorised-presentations/rivastigmine-teva-epar-all-authorised-presentations_fr.pdf)

íslenska (IS) (228.86 KB - PDF)

**First published:**

08/05/2009

**Last updated:**

27/09/2012

[View](/is/documents/all-authorised-presentations/rivastigmine-teva-epar-all-authorised-presentations_is.pdf)

italiano (IT) (228.36 KB - PDF)

**First published:**

08/05/2009

**Last updated:**

27/09/2012

[View](/it/documents/all-authorised-presentations/rivastigmine-teva-epar-all-authorised-presentations_it.pdf)

latviešu valoda (LV) (308.06 KB - PDF)

**First published:**

08/05/2009

**Last updated:**

27/09/2012

[View](/lv/documents/all-authorised-presentations/rivastigmine-teva-epar-all-authorised-presentations_lv.pdf)

lietuvių kalba (LT) (298.36 KB - PDF)

**First published:**

08/05/2009

**Last updated:**

27/09/2012

[View](/lt/documents/all-authorised-presentations/rivastigmine-teva-epar-all-authorised-presentations_lt.pdf)

magyar (HU) (308.18 KB - PDF)

**First published:**

08/05/2009

**Last updated:**

27/09/2012

[View](/hu/documents/all-authorised-presentations/rivastigmine-teva-epar-all-authorised-presentations_hu.pdf)

Malti (MT) (305.81 KB - PDF)

**First published:**

08/05/2009

**Last updated:**

27/09/2012

[View](/mt/documents/all-authorised-presentations/rivastigmine-teva-epar-all-authorised-presentations_mt.pdf)

Nederlands (NL) (227.93 KB - PDF)

**First published:**

08/05/2009

**Last updated:**

27/09/2012

[View](/nl/documents/all-authorised-presentations/rivastigmine-teva-epar-all-authorised-presentations_nl.pdf)

norsk (NO) (228.31 KB - PDF)

**First published:**

08/05/2009

**Last updated:**

27/09/2012

[View](/no/documents/all-authorised-presentations/rivastigmine-teva-epar-all-authorised-presentations_no.pdf)

polski (PL) (307.29 KB - PDF)

**First published:**

08/05/2009

**Last updated:**

27/09/2012

[View](/pl/documents/all-authorised-presentations/rivastigmine-teva-epar-all-authorised-presentations_pl.pdf)

português (PT) (228.76 KB - PDF)

**First published:**

08/05/2009

**Last updated:**

27/09/2012

[View](/pt/documents/all-authorised-presentations/rivastigmine-teva-epar-all-authorised-presentations_pt.pdf)

română (RO) (295.64 KB - PDF)

**First published:**

08/05/2009

**Last updated:**

27/09/2012

[View](/ro/documents/all-authorised-presentations/rivastigmine-teva-epar-all-authorised-presentations_ro.pdf)

slovenčina (SK) (305.67 KB - PDF)

**First published:**

08/05/2009

**Last updated:**

27/09/2012

[View](/sk/documents/all-authorised-presentations/rivastigmine-teva-epar-all-authorised-presentations_sk.pdf)

slovenščina (SL) (237.64 KB - PDF)

**First published:**

08/05/2009

**Last updated:**

27/09/2012

[View](/sl/documents/all-authorised-presentations/rivastigmine-teva-epar-all-authorised-presentations_sl.pdf)

Suomi (FI) (228.53 KB - PDF)

**First published:**

08/05/2009

**Last updated:**

27/09/2012

[View](/fi/documents/all-authorised-presentations/rivastigmine-teva-epar-all-authorised-presentations_fi.pdf)

svenska (SV) (228.48 KB - PDF)

**First published:**

08/05/2009

**Last updated:**

27/09/2012

[View](/sv/documents/all-authorised-presentations/rivastigmine-teva-epar-all-authorised-presentations_sv.pdf)

## Product details

Name of medicine Rivastigmine Teva Active substance rivastigmine International non-proprietary name (INN) or common name rivastigmine Therapeutic area (MeSH)

- Dementia
- Alzheimer Disease
- Parkinson Disease

Anatomical therapeutic chemical (ATC) code N06DA03

### Pharmacotherapeutic group

Anticholinesterases

### Therapeutic indication

Symptomatic treatment of mild to moderately severe Alzheimer's dementia.

Symptomatic treatment of mild to moderately severe dementia in patients with idiopathic Parkinson's disease.

## Authorisation details

EMA product number EMEA/H/C/001044

Generic

This is a generic medicine, which is developed to be the same as a medicine that has already been authorised, called the reference medicine. A generic medicine contains the same active substance(s) as the reference medicine, and is used at the same dose(s) to treat the same disease(s). For more information, see [Generic and hybrid medicines](/node/69107) .

Marketing authorisation holder

Teva Pharma B.V.

Computerweg 10

Marketing authorisation issued 17/04/2009 Withdrawal of marketing authorisation 10/09/2012 Revision 4

## Assessment history

Expand section

Collapse section

## Changes since initial authorisation of medicine

Rivastigmine Teva : EPAR - Procedural steps taken and scientific information after authorisation

English (EN) (279.36 KB - PDF)

**First published:** 06/07/2009

**Last updated:** 27/09/2012

[View](/en/documents/procedural-steps-after/rivastigmine-teva-epar-procedural-steps-taken-and-scientific-information-after-authorisation_en.pdf)

## Initial marketing authorisation documents

Rivastigmine Teva : EPAR - Public assessment report

English (EN) (628.59 KB - PDF)

**First published:** 13/05/2009

**Last updated:** 27/09/2012

[View](/en/documents/assessment-report/rivastigmine-teva-epar-public-assessment-report_en.pdf)

Committee for medicinal products for human use, summary of positive opinion for Rivastigmine Teva

Reference Number: EMEA/CHMP/100894/2009

English (EN) (32.86 KB - PDF)

**First published:** 18/02/2009

**Last updated:** 18/02/2009

[View](/en/documents/smop-initial/committee-medicinal-products-human-use-summary-positive-opinion-rivastigmine-teva_en.pdf)

**This page was last updated on** 27/09/2012

## Share this page

[Back to top](#main-content)